Literature DB >> 16133732

The natural course of non-classic Pompe's disease; a review of 225 published cases.

Léon P F Winkel1, Marloes L C Hagemans, Pieter A van Doorn, M Christa B Loonen, Wim J C Hop, Arnold J J Reuser, Ans T van der Ploeg.   

Abstract

Pompe's disease is a neuromuscular disorder caused by deficiency of lysosomal acid alpha-glucosidase. Recombinant human alpha- glucosidase is under evaluation as therapeutic drug. In light of this development we studied the natural course of cases not fitting the definition of classic infantile Pompe's disease. Our review of 109 reports including 225 cases shows a continuous spectrum of phenotypes. The onset of symptoms ranged from 0 to 71 years. Based on the available literature, no criteria to delineate clinical sub-types could be established.A common denominator of these cases is that first symptoms were related to or caused by muscle weakness. In general, patients with a later onset of symptoms seemed to have a better prognosis. Respiratory failure was the most frequent cause of death. CK, LDH, ASAT, ALAT and muscle glycogen levels were frequently but not always elevated. In most cases a muscle biopsy revealed lysosomal pathology, but normal muscle morphology does not exclude Pompe's disease. In 10% of the cases in which the enzyme assay on leukocytes was used, a normal alpha-glucosidase activity was reported. Data on skeletal muscle strength and function, pulmonary function, disability, handicap and quality of life were insufficiently reported in the literature. Studies of non-classic Pompe's disease should focus on these aspects, before enzyme replacement therapy becomes generally available.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16133732     DOI: 10.1007/s00415-005-0922-9

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  127 in total

1.  Alpha-glucosidase deficiency in a child.

Authors:  R D Griffiths; D Heaf; A Cooper; I B Sardharwalla
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

2.  Two extremes of the clinical spectrum of glycogen storage disease type II in one family: a matter of genotype.

Authors:  M A Kroos; M Van der Kraan; O P Van Diggelen; W J Kleijer; A J Reuser
Journal:  Hum Mutat       Date:  1997       Impact factor: 4.878

3.  Pathological features of glycogen storage disease type II highlighted in the knockout mouse model.

Authors:  A G Bijvoet; H Van Hirtum; M Vermey; D Van Leenen; A T Van Der Ploeg; W J Mooi; A J Reuser
Journal:  J Pathol       Date:  1999-11       Impact factor: 7.996

4.  Cardiac arrhythmias and the adult form of type II glycogenosis.

Authors:  M Francesconi; E Auff
Journal:  N Engl J Med       Date:  1982-04-15       Impact factor: 91.245

5.  Type II glycogenosis and thyroxine binding globulin deficiency in the same family.

Authors:  P Manta; P Kontoleon; A Panousopoulou; N Kalfakis; H Christomanou; P Papapetrou; C Papageorgiou
Journal:  Funct Neurol       Date:  1996 Mar-Jun

6.  Increased excretion of a glucose-containing tetrasaccharide in the urine of a patient with glycogen storage disease type II (Pompe's disease).

Authors:  P Hallgren; G Hansson; K G Henriksson; A Häger; A Lundblad; S Svensson
Journal:  Eur J Clin Invest       Date:  1974-12-05       Impact factor: 4.686

7.  Acid maltase deficiency: treatment of respiratory insufficiency with cuirass respirator.

Authors:  A E de Jager; A F Meinesz
Journal:  J Neurol       Date:  1983       Impact factor: 4.849

Review 8.  Glycogenosis type II (acid maltase deficiency).

Authors:  A J Reuser; M A Kroos; M M Hermans; A G Bijvoet; M P Verbeet; O P Van Diggelen; W J Kleijer; A T Van der Ploeg
Journal:  Muscle Nerve Suppl       Date:  1995

9.  Acid maltase deficiency (type II glycogenosis). Morphological and biochemical study of a childhood phenotype.

Authors:  J J Martin; T De Barsy; J G Leroy; G Palladini
Journal:  J Neurol Sci       Date:  1976-11       Impact factor: 3.181

10.  [Pseudodystrophic muscle glycogenosis in adults. (Acid maltase deficiency syndrome) (author's transl)].

Authors:  F Gullotta; H Stefan; H Mattern
Journal:  J Neurol       Date:  1976       Impact factor: 4.849

View more
  91 in total

1.  36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy.

Authors:  Caroline Regnery; Cornelia Kornblum; Frank Hanisch; Stefan Vielhaber; Nicola Strigl-Pill; Birgit Grunert; Wolfgang Müller-Felber; Franz Xaver Glocker; Matthias Spranger; Marcus Deschauer; Eugen Mengel; Benedikt Schoser
Journal:  J Inherit Metab Dis       Date:  2012-01-31       Impact factor: 4.982

2.  Qualitative and quantitative skeletal muscle ultrasound in late-onset acid maltase deficiency.

Authors:  Craig M Zaidman; Elizabeth C Malkus; Catherine Siener; Julaine Florence; Alan Pestronk; Muhammad Al-Lozi
Journal:  Muscle Nerve       Date:  2011-07-13       Impact factor: 3.217

Review 3.  Glycogen storage disease manifested as gout and myopathy: three case reports and literature review.

Authors:  Wei Zhang; Chun-de Bao; Yue-ying Gu; Shuang Ye
Journal:  Clin Rheumatol       Date:  2007-12-18       Impact factor: 2.980

Review 4.  Glycogen storage disease type II: clinical overview.

Authors:  M Di Rocco; D Buzzi; M Tarò
Journal:  Acta Myol       Date:  2007-07

Review 5.  [Diagnosis and therapy of late onset Pompe disease].

Authors:  A Schüller; C Kornblum; M Deschauer; M Vorgerd; B Schrank; E Mengel; Z Lukacs; D Gläser; P Young; U Plöckinger; B Schoser
Journal:  Nervenarzt       Date:  2013-12       Impact factor: 1.214

6.  Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.

Authors:  S Strothotte; N Strigl-Pill; B Grunert; C Kornblum; K Eger; C Wessig; M Deschauer; F Breunig; F X Glocker; S Vielhaber; A Brejova; M Hilz; K Reiners; W Müller-Felber; E Mengel; M Spranger; Benedikt Schoser
Journal:  J Neurol       Date:  2009-08-01       Impact factor: 4.849

7.  Adult onset Pompe disease associated with multiple sclerosis.

Authors:  Maria Sepulveda; Elvira Munteis; Miguel A Rubio; Jordi Pascual; Jaume Roquer
Journal:  J Neurol       Date:  2011-05-26       Impact factor: 4.849

8.  Adult onset glycogen storage disease type II (adult onset Pompe disease): report and magnetic resonance images of two cases.

Authors:  Andrew Del Gaizo; Sima Banerjee; Michael Terk
Journal:  Skeletal Radiol       Date:  2009-12       Impact factor: 2.199

9.  Systemic Delivery of AAVB1-GAA Clears Glycogen and Prolongs Survival in a Mouse Model of Pompe Disease.

Authors:  Allison M Keeler; Marina Zieger; Sophia H Todeasa; Angela L McCall; Jennifer C Gifford; Samantha Birsak; Sourav R Choudhury; Barry J Byrne; Miguel Sena-Esteves; Mai K ElMallah
Journal:  Hum Gene Ther       Date:  2018-07-25       Impact factor: 5.695

10.  Fatigue: an important feature of late-onset Pompe disease.

Authors:  Marloes L C Hagemans; Sabine P M van Schie; A Cecile J W Janssens; Pieter A van Doorn; Arnold J J Reuser; Ans T van der Ploeg
Journal:  J Neurol       Date:  2007-03-02       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.